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Abstract 
 
 
Background: 
Epidemiology of hepatitis B infection in the Middle East in 2001 showed 
that the prevalence in Sudan was between 16–20%. Community–based 
surveys are recommended as they provide more accurate information that 
can be generalized than hospital–based surveys. WHO estimated that among 
children, new hepatitis B carrier will be reduced at least 80% through 
integration of hepatitis B vaccine into national immunization programmes. This 
study is intended to conduct a community–based sero–epidemiologic survey 
to estimate hepatitis B markers among children <10 years in Khartoum State. 
Such type of studies shall provide baseline data that would be of priceless 
benefit for any further impact studies in future in the country. It has been a 
perfect opportunity to have this study being completed just before the 
introduction of hepatitis B vaccine into EPI in the country. 
Design: 
Cross–sectional community–based survey. 
Settings: 
Khartoum State, as a study area; more or less it represents the whole country 
with its diverse demographic features. Five hundred Blood Samples were 
taken from children aged 0–10 years old and tested for anti–HBc, HBsAg, 
anti–HBs, HBeAg, and anti–HBe.  
Objectives: 
• To measure the sero–prevalence of HB markers (HBsAg, HBeAg, 
Anti–HBs, Anti–HBc and Anti–HBe) in children <10 years of age in 
Khartoum State. 
• To determine the relationship between selected risk factors and 
presence of positive HBV markers among children <10 years of age 
in Khartoum State. 
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Results:  
The study showed that one hundred twenty four children 24.8% 
{95%CI, 24.84%–24.76%} were positive for Anti–HBc. 14 of them 11.3% {95% 
CI, 11.21%–11.39%} were positive for HBsAg. No anti–HBs were detected for 
those who were negative i.e. they were not immuned. Out of those 14 children 
who were positive for HBsAg 11 (78.6%) were also found to be positive for 
HBeAg. Anti–HBe was found positive in 1 (33.3%) out of the 3 negative.  
As far as the risk factors are concerned, there is a statistical significant 
relation between Anti–HBc positive marker and family tribe (P=0.047). 
Refugees especially those from endemic areas (P=0.036). Child history of 
blood or blood products transfusion (P=0.017). Child history of chronic illness 
required regular injection (P=0.023) and the type of chronic disease that 
required regular injection (P=0.031). 
No statistical significant relation between other HBV markers and the 
other studied risk factors.  
Conclusion:  
It is concluded that the prevalence rate of current or past HB infection 
among children <10 years old in Khartoum States was 24.8%. The prevalence 
rate of chronic carriers was 11.3%. There was statistical significant relation 
between presence of anti–HBc and family tribe, refugees, history of blood or 
blood products transfusion and chronic illness that required regular exposure 
to injections. It was recommended that HB vaccine be included in the routine 
immunization schedule in Sudan. Another impact study has to be conducted 
after five to ten years. 
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Introduction  
 
 
Introduction: 
Viral hepatitis is one of the major diseases of mankind and is a serious 
global public health problem. Of the five viruses that are known to cause hepatitis 
in humans, hepatitis B virus is responsible for the majority of the worldwide 
hepatitis disease burden. Two billion people alive today have been infected 
worldwide and over 520,000 die each year (50,000 from acute hepatitis B and 
470,000 from cirrhosis or liver cancer). It is estimated that there are 280 million 
carriers world–wide representing more than 5% of the global population. In the 
Middle East, Indian Sub–Continent, Amazon, the southern parts of eastern and 
central Europe about 5% are chronically infected. Infection is less common in 
Western Europe and North America, where less than 1% is chronically infected (1–
3).  
The risk of developing chronic HBV infection varies inversely with age; 
approximately 80−90% of infants infected during the first year of life, 30%−60% of 
children infected between 1 and 4 years of age, and 5% of adults who develop 
infection become carriers and die of liver cancer or cirrhosis later in life. The risk of 
death from HBV–related liver cancer or cirrhosis is approximately 25% for persons 
who become chronically infected during childhood (1, 4, 5). 
The frequency of HBV infection varies markedly in different parts of the 
world. Approximately 45% of the world's population live in Africa and Asia where 
the prevalence of chronic HBV infection is high (>8% of the population is HBsAg 
positive), 43% live in areas where the prevalence is moderate (2 to 7% of the 
population is HBsAg positive), and 12% live in Great Britain, Canada, United 
States, Scandinavia, and some other European Nations where there is low 
endemicity (<2% of the population is HBsAg positive) (1, 3, 5, 6, 7). 
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Sudan, as other developing countries, is classified as a hyper endemic area 
where the prevalence of hepatitis B among population is estimated to be >8%. 
Some studies were done among new borne infants in hospital and another study to 
review the epidemiology of hepatitis B virus infection in the Middle East in 2001 
showed that the prevalence in Sudan between 16–20% (8). It is evident that HBV 
infection is a serious public health problem in the region and many questions 
specific to the region remain unanswered (8). In Sudan the early infection passed 
without detection, many studies which were conducted to detect the prevalence of 
hepatitis B among adults indicate a prevalence range from 10%–26%. 
Community–based surveys are recommended as they provide more accurate 
information that can be generalized un like hospital–based surveys which are of 
limited values (9–10). This study is intended to conduct a community–based sero–
epidemiologic survey to estimate hepatitis B markers among children <10 years in 
Khartoum State. Such type of studies shall provide a baseline data that would be 
of priceless benefit for any further impact studies in the country in future. Khartoum 
is the capital state which accommodates more than 5 million inhabitants (Central 
Bureau of Statistic estimate, 2004) from all over Sudan with more than 200 
different tribes. It represents the whole country with its diverse demographic 
features. Sudan is planning to introduce HB vaccine into its routine immunization 
schedule. As it was estimated by WHO that as a result of integration of hepatitis B 
vaccine into national immunization programmes, new hepatitis B carrier rate will be 
reduced at least by 80%. Countries with high, low, or intermediate endemicity that 
had implement early universal vaccination had shown a fall in acute hepatitis B in 
adults and in hepatocellular carcinoma (HCC) in children, lower prevalence of 
hepatitis B surface antigen (HBsAg) carriers in children and adolescents. It has 
been a perfect opportunity to have this study being completed just before the 
introduction of hepatitis B vaccine into EPI programme in the country (1). 
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Rationale:  
Hepatitis B vaccine has been introduced into immunization programmes in 
developed countries for more than 20 years. Developing countries have failed to 
introduce the vaccine not only because of its cost but also because of lack of local 
data on the burden of disease in most of those countries. 
The World Health Assembly 1992 stated that: "Hepatitis B vaccine should 
be integrated into national immunization programmes in all countries by 1997". 
This study will contribute to and support the decision making process of selecting 
the appropriate target group and further studies in future which might be needed to 
study the possible impact of the introduction of the vaccine in the country. 
There isn’t enough information to document the burden of disease in Sudan 
especially among children <10 years of age. 
In addition to the above mentioned points, it was recommended from a 
previous study of epidemiology of hepatitis B virus infection in the Middle East in 
2001 that; a community–based survey is highly needed in countries of the region 8. 
Sudan was classified by WHO as a hyper–endemic area where the 
prevalence HBV infection >8%, and the country was supported by the Global 
Alliance of Vaccine and Immunization (GAVI) to introduce HB vaccine into routine 
immunization to all children <1 year of age. The new vaccine "Hepatitis B vaccine" 
will be introduced in 2005 and hence, this study will serve as a base line study for 
HB infection prevalence in children before the introduction of the vaccine. 
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Objectives 
 
 
General 
Objective 
To determine the sero–epidemiology of hepatitis B 
markers in children <10 years of age in Khartoum 
State, 2004. 
 
 
 
 
Specific 
Objectives 
• To measure the sero–prevalence of HB markers (HBsAg, 
HBeAg, Anti–HBs, Anti–HBc and Anti–HBe) in children 
<10 years of age in Khartoum State. 
 
• To determine the relationship between selected risk 
factors and presence of positive HBV markers among 
children <10 years of age in Khartoum State. 
 
Sero–epidemiology of Hepatitis B among 
children <10 yrs – Khartoum State, 2004 5 
 
Literature Review 
 
Background Information: 
Hepatitis is a general term meaning inflammation of the liver and can be 
caused by a variety of different viruses such as hepatitis B, C, D, and E. since the 
development of jaundice is a characteristic feature of liver disease. A correct 
diagnosis can only be made by testing patients’ sera for the presence of specific 
anti–viral antigens or antibodies. (1, 2, 3) 
Of the many viral causes of human hepatitis few are of global importance 
than hepatitis B virus (HBV), which a serious and common infectious disease of 
the liver affecting millions of people throughout the world. It has also called serum 
hepatitis. Infection occurs very often in early childhood when it is asymptomatic 
and often lead to the chronic carrier state. (1, 2, 5)  
Australia antigen, which is later called hepatitis B surface antigen (HBsAg), 
was first described in 1965, and the Dane particle (complete hepatitis B virion) was 
identified in 1970. Identification of serologic markers for HBV infection followed, 
which helped clarify the natural history of the disease. Ultimately, HBsAg was 
prepared in quantity and now comprises the immunogen in highly effective 
vaccines for prevention of HBV infection. 
Epidemics of jaundice have been described throughout history and were 
particularly common during various wars in the 19th and 20th centuries. While many 
of these outbreaks were due to hepatitis A, it is likely that epidemic transmission of 
hepatitis B also occurred in settings where the use of blood–containing products 
was common. The recognition of a form of hepatitis that was transmitted by direct 
inoculation of blood or blood products fever vaccine recipients was linked to a 
specific lot of vaccine that contained human serum. A follow–up study in the 1980s 
demonstrated that 97% of recipients of the serum–containing vaccine had 
serologic evidence of HBV infection compared to 13% of persons who received 
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yellow fever vaccine that did not contain human serum, confirming that HBV was 
the cause of this outbreak. (5)  
The discovery of the etiologic agent of hepatitis B and the development of 
safe and effective vaccines constitute one of the remarkable scientific 
achievements of the 20th century. In the 19th century, Virchow had proposed that 
the pathogenesis of acute hepatitis was due to a plug of mucus in the ampulla of 
was first documented by Lurman in Bremen, Germany, in 1883, during a smallpox 
immunization campaign. Thousands of persons received vaccine that had been 
prepared from human lymph, of 1,289 shipyard workers who received this vaccine, 
191 (15%) developed jaundice several weeks to 8 months later; jaundice did not 
occur among unvaccinated workers. In the first part of the 20th century, outbreaks 
of “long–incubation” hepatitis were described in a variety of risk groups including 
persons who attended clinics for venereal diseases, diabetes, and tuberculosis; 
patients who received blood transfusions; Persons inoculated with mumps or 
measles convalescent–phase serum; and military personnel who received yellow 
fever vaccine. This hypothesis was disputed when pathologic studies revealed 
diffuse hepatic inflammation in persons with acute jaundice, suggesting an 
infectious cause. Studies of human volunteers in the 1930s and 1940s provided 
convincing evidence of a viral cause with at least two etiologic agents. (5) 
In 1947, MacCallum and Bauer proposed the current nomenclature of 
hepatitis A for infectious hepatitis and hepatitis B for “homologous serum” hepatitis. 
At that time, it was known that the epidemiology of the two diseases differed. 
Hepatitis A was transmitted by the fecal oral route, had an incubation period of 2 to 
6 weeks, and was primarily a disease of younger children. In contrast, hepatitis B 
was transmitted by per cutaneous exposure to blood products, had a longer 
incubation period (ranging from 2 to 6 months), and occurred more often in adults. 
These observations were confirmed in a series of studies which showed that the 
MS–1 strain of hepatitis (i.e., hepatitis A virus) was transmitted by the fecal–oral 
route and had an incubation period of 30 to 38 days. In contrast, the MS–2 strain of 
hepatitis (i.e., hepatitis B virus) had an incubation period of 41–108 days and was 
transmitted by per–cutaneous exposure. These studies also confirmed the 
existence of homologous immunity after infection with HAV or HBV. 
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The discovery of the etiological agent for hepatitis B is among the 
remarkable scientific achievements of the 20th century. The first evidence that a 
form of hepatitis was transmitted by direct inoculation of blood or blood products 
was discovered when an outbreak of hepatitis occurred after a smallpox 
immunization campaign among shipyard workers in Bremen, Germany in 1883. 
Further evidence of a parenterally–transmitted form of viral hepatitis was 
documented early in the 20th Century, when numerous outbreaks of jaundice 
among patients attending venereal disease and diabetic clinics were associated 
with reuse of syringes and needles without sterilization (1, 3, 5, 11). 
The discovery of the etiological agent for hepatitis B is among the 
remarkable scientific achievements of the 20th century. In 1965, Blumberg and 
colleagues described an isoprecipitin that was present in the serum of Australian 
aboriginies, termed Australia antigen. This antigen was found to have a variable 
distribution in healthy populations in different geographical areas of the world, with 
a low prevalence (<1%) in North America and Europe and a high prevalence (6%–
25%) in the tropics and Southeast Asia (1, 3, 5).  
In addition, the antigen was found to occur more commonly among patients 
who had received multiple transfusions and blood products. The Australia antigen 
was subsequently shown to be related to HBV infection and was ultimately shown 
to be the surface protein of HBV (1, 3, 5). 
Within a decade after the discovery of Australia antigen, HBV was 
visualized by electron microscopy as 42 nm viral particles (Dane particles) that 
reacted with anti–sera to Australia antigen. Immunoassays for the detection of 
antigens and antibodies associated with HBV infection were developed. The 
development of sensitive and specific tests to detect HBV infection allowed 
investigators to define the natural history of HBV infection and to develop 
strategies to prevent transmission, including the screening of blood for HBsAg to 
prevent transfusion–associated hepatitis B. In addition, units of blood that tested 
positive for antibody to HBsAg (anti–HBs) were used for the preparation of 
hepatitis B immune globulin (HBIG), which was shown to be effective in preventing 
or modifying the course of HBV infection. Beginning in the early 1980s, plasma–
derived hepatitis B vaccines were manufactured and licensed in a number of 
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countries. Subsequently, the development of recombinant DNA technology 
enabled the expression of large quantities of HBsAg in yeast and mammalian cells, 
which led to the production and licensing of recombinant hepatitis B vaccines. The 
recognition of hepatitis B as a major global cause of morbidity and mortality led to 
a worldwide effort to reduce transmission of HBV and HBV–related chronic liver 
disease through routine infant vaccination (1, 3, 5, 11). 
Clinical Description 
Acute Hepatitis B: 
The clinical manifestations of acute hepatitis B are indistinguishable from 
other causes of viral hepatitis. The incubation period is usually 3−4 months, with a 
range of 6 weeks to 6 months. The prodromal phase of disease is quite variable, 
and is characterized by insidious onset of constitutional symptoms that may 
include malaise, anorexia, nausea, occasional vomiting, low grade fever, myalgias, 
and easy fatigability. In 5%–10% of patients, a serum sickness–like syndrome may 
develop during the prodromal phase that is characterized by arthralgias or arthritis, 
rash, and angioedema. Other extra hepatic manifestations that have rarely been 
reported in association with acute HBV infection include polyarteritis nodosa, 
membranous glomerulonephritis, Gianotti–Crosti Syndrome and aplastic anemia. 
In patients with icteric hepatitis, jaundice usually develops within 1–2 weeks after 
onset of illness; dark urine and clay–colored stools may appear 1–5 days before 
onset of clinical jaundice. During the icteric phase, constitutional prodromal 
symptoms usually diminish, and right upper quadrant pain may develop as the liver 
becomes enlarged and tender. In 10%–30% of patients with acute hepatitis B, 
myalgias and arthralgias have been described without jaundice or other clinical 
signs of hepatitis; in one–third of these patients, a maculopapular rash appears 
with joint symptoms. Clinical signs and symptoms usually resolve within 1 to 3 
months (1, 3, 11). 
The severity of illness associated with acute hepatitis B usually does not 
require hospitalisation. Fulminant liver failure occurs in approximately 0.5%–1% of 
infected adults, but rarely in infected infants and children. Higher rates of fulminant 
hepatitis may occur in association with HBV–hepatitis delta virus co–infection. 
Patients with fulminant hepatitis usually present with features of hepatic 
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encephaopathy, including disturbances in sleep patterns, asterixis, mental 
confusion, disorientation, somnolence, and coma. The case–fatality rate in patients 
who develop fulminant hepatitis is about 60%–70%, unless liver transplantation 
can be performed (1, 3, 5, 11). 
Chronic HBV Infection: 
Most of the disease burden associated with HBV infection is in persons who 
develop chronic infection, which is commonly defined as the presence of HBsAg in 
serum for at least 6 months. Chronic HBV infection is typically characterized by 
three phases in persons who acquire infection perinatally, and two phases in 
persons who acquire infection as older children and adults Perinatally–acquired 
infections usually have a period of active viral replication without active liver 
disease, which is followed by a replicate phase with active liver disease, and a 
later phase with low or absent viral replication and remission of active liver 
disease. The latter two phases generally only occur in persons who acquire 
infection as older children and adults. 
The initial phase of perinatally–acquired infections is characterized by high 
levels of virus replication. These patients are typically HBeAg positive and have 
high levels of HBV DNA in serum; however, they usually have no evidence of 
active liver disease, with normal alanine aminotransferase levels, no signs or 
symptoms of hepatitis, and minimal necroinflammatory activity on liver biopsy. The 
absence of liver disease despite high levels of viral replication is believed to be due 
to immune tolerance. The initial phase of infection usually lasts 10 to 30 years. 
During this time, rates of spontaneous HBeAg sero–conversion are less than 1% 
per year. This low rate of viral clearance accounts for the high prevalence of 
HBeAg among women of childbearing age in areas of the world where there are 
high rates of perinatal HBV transmission (1, 3, 5, 7, 11). 
The second phase of perinatal–acquired chronic infection and the first 
phase of chronic infection in older children and adults are characterized by high 
levels of virus replication with active liver disease. These patients are usually 
HBeAg–positive with high levels of HBV DNA in serum. During this phase, fibrosis 
of the liver develops, which can lead to cirrhosis, an irreversible form of liver injury. 
The rate of spontaneous clearance of HBeAg is approximately 10% to 20% per 
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year both in patients with perinatal–aquired infections and in patients who acquire 
infection at older ages most patients are asymptomatic during this phase, but 
HBeAg sero–conversion may be accompanied by symptomatic exacerbations. 
Hepatic decompensation may occur in about 2% of patients during these 
exacerbations, which can rarely lead to death from hepatic failure. In some patients 
with suboptimal immune response and abortive immune clearance, repeated 
exacerbations may occur with intermittent clearance of HBV DNA from serum and 
transient loss of HBeAg. Repeated episodes of necroinflammation may increase 
the risk of developing severe chronic liver disease. Ultimately, the outcome of 
chronic infection depends primarily on the severity of liver disease at the time 
HBeAg sero–conversion occurs, and HBV replication is arrested (1, 3, 5, 7, 11). 
The last phase of chronic HBV infection (i.e. third phase of perinatal–
acquired infection and second phase of chronic infection acquired at older ages) is 
characterized by low or absent levels of virus replication and remission of active 
liver disease. These patients are typically HBeAg negative, antibody to HBeAg 
positive, and have low or undetectable HBV DNA in serum. Most of patients who 
clear HBeAg have normal ALT levels and resolution of necroinflammation on liver 
biopsy, indicating resolution of active liver disease. However, a small percentage 
continues to have moderate levels of HBV replication, elevated ALT levels, and 
chronic inflammation on liver biopsy despite HBeAg sero–conversion. These 
patients can also have residual liver disease, and can be misdiagnosed as having 
chronic liver disease of unknown etiology if they are HBsAg–negative. Patients 
who clear HBeAg generally remain HBsAg positive for long periods of time, even in 
the absence of detectable HBV DNA. However, HBV DNA can be detected in up to 
50% of these patients by PCR even after clearance of HBsAg. 
The majority of persons with chronic HBV infection remains healthy and dies 
of unrelated causes. In addition, persons with severe chronic liver disease are 
often asymptomatic until late in the course of their disease. However, findings of 
long term clinical follow–up studies indicate that chronic HBV infection is an 
important cause of morbidity and mortality worldwide. Persons with chronic HBV 
infection are also at high risk of developing HCC, which is the seventh most 
frequent human cancer (1, 3, 5, 11). 
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Diagnosis: 
Serologic tests are commercially available for a variety of antigens and 
antibodies associated with HBV infection, including HBsAg, anti–HBs, and total 
(IgG and IgM) antibody to HBcAg (anti–HBc), IgM anti–HBc, HBeAg, and antibody 
to HBeAg (anti–HBe). In addition, hybridization assays and gene amplification 
techniques (e.g. polymerase chain reaction) are available to detect HBV DNA (1, 4, 
5, 11, 12, 13). 
Serologic tests are commercially available for a variety of antigens and 
antibodies associated with HBV infection, including HBsAg, anti–HBs, and total 
(IgG and IgM) antibody to HBcAg (anti–HBc), IgM anti–HBc, HBeAg, and antibody 
to HBeAg (anti–HBe).  
HBs antigen: Hepatitis B surface antigen (HBsAg) is borne by surface viral 
proteins, i.e. viral proteins anchored at the surface of viral envelopes. The 
presence of HBsAg is thus a sign of HBV envelope production at the acute 
phase of infection or in chronic HBV carriers, but not a marker of viral 
replication (1,11. 12, 13).  
HBe antigen: Hepatitis B envelop antigen (HBeAg) is borne by a nonstructural 
protein produced during viral replication in hepatocytes infected by so–
called "wild–type" HBV and then released into the general circulation. When 
present, HBeAg is associated with HBV DNA detection. In contrast, so–
called "pre–core mutant" HB viruses are unable to produce the HBe protein. 
In these patients, HBV DNA is detected in the absence of HBeAg. 
Therefore, HBeAg is not a reliable marker of HBV replication. 
Anti–HBs antibodies: Their appearance a few weeks after resolution of acute 
hepatitis B is associated with disappearance of HBsAg (HBs sero–
conversion) and is considered the marker of resolution of HBV infection. 
These antibodies can also rarely appear after HBsAg disappearance in non 
replicative chronic HBV carriers, either spontaneously or following 
successful antiviral therapy. They generally persist for life, but may become 
undetectable after few years (1, 11, 12, 13).  
Sero–epidemiology of Hepatitis B among 
children <10 yrs – Khartoum State, 2004 12 
Total anti–HBc antibodies: Anti–HBc antibodies are directed against a viral capsid 
epitope or core antigen. They appear early during infection and remain 
detectable for life, whatever the outcome of infection. They can be present 
in the absence of both HBsAg and anti–HBs antibodies, during the 
convalescent period following acute hepatitis B before the appearance of 
anti–HBs antibodies, or in patients who resolved infection but lost detectable 
anti–HBs antibodies. Anti–HBc is therefore detected in anyone who has 
been infected with HBV and it indicates past infection, either acute or 
chronic. 
Anti–HBc IgM: High titers of anti–HBc IgM are present early at the acute stage of 
HBV infection. They disappear after the appearance of anti–HBs antibodies 
when infection resolves. Low amounts of anti–HBc IgM can also be found 
with ultra–sensitive EIA techniques in patients with chronic HBV infection, 
bearing witness to a strong and adapted anti–HBV immune response. 
Anti–HBe antibodies: In patients infected with a "wild–type" HBV, anti–HBe 
antibodies appear after HBeAg disappearance (HBe sero–conversion) when 
replication ceases, either spontaneously or following successful antiviral 
treatment. In patients infected with a "precore mutant" HBV, anti–HBe 
antibodies are present whether or not HBV replicates. HBV DNA detection 
is thus needed to distinguish between patients who have sero–converted to 
HBeAg and those with pre–core mutant infections and ongoing HBV 
replication (1, 11, 12, 13). 
No specific treatment is available for persons with acute hepatitis B. 
Supportive care is the mainstay of therapy for these persons. 
Epidemiology: 
Hepatitis B virus is transmitted by either percutaneous or mucous 
membrane contact with infected blood or other body fluids. Some studies done to 
detect the risk of blood transfusion e.g. study done in Ghana 2000 (14). The virus is 
found in highest concentrations in blood and serous exudates, lower 
concentrations are found in various body secretions, including saliva, semen and 
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vaginal fluid. The primary routes of transmission are perinatal, child–to–child, 
sexual contact, and percutaneous exposures (e.g., unsafe injections and blood 
transfusions). HBV is not spread by air, food or water, and many epidemiological 
studies were done concerning the route of transmission and revealed different 
routes among different countries e.g. study done in 2001 to review epidemiology of 
HB in Middle East region and they found different routes from country to country 
(8). Many studies were done for HBV epidemiology among adults and children and 
revealed different results (14, 15, 16, 17, 18, 19). 
Perinatal transmission: 
HBV transmission from infected mothers to their newborn infants is a major 
source of HBV infections in many countries. Perinatal transmission usually 
happens at the time of birth; in utero transmission is relatively rare, accounting for 
<2% of infections transmitted from mother to infant in most studies. Although HBV 
can be detected in breast milk, there is no evidence that HBV can be spread by 
breast feeding. The risk of perinatal transmission is higher from mothers with high 
titers of HBV DNA, which generally correlates with the presence of HBeAg. The 
risk of transmitting chronic HBV infection is >70% from mothers who are HBeAg–
positive and <10% from those who are HBeAg–negative. Most perinatal HBV 
infections occur among infants of pregnant women with chronic HBV infection as 
was evident in many studies for example studies done in the Middle East Region 
(8), another study done in Iran 1991 (15), study done in Sudan 2003 (10).  
Child–to–child transmission: 
HBV transmission from child–to–child accounts for a high proportion of HBV 
infections worldwide. Child–to–child HBV transmission most commonly occurs in 
households of chronically infected persons, but has also been recognized in child 
day care centers and in schools. Many studies for children route of transmission 
were conducted in USA (20). The most probable mechanisms of child–to–child 
spread involve contact of dermatologic lesions, breaks in the skin, or mucous 
membranes with blood or skin lesion secretions. HBV may also spread because of 
contact with saliva through bites or other breaks in the skin, and as a consequence 
of the pre–mastication of food. In addition the virus may spread from inanimate 
objects such as shared towels or toothbrushes, since it can survive for at least 
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seven days outside the body and can be found in high titres on objects, even in the 
absence of visible blood (1, 3, 11).  
Sexual transmission: 
HBV is efficiently transmitted by sexual contact, which can account for a 
high proportion of new HBV infections among adolescents and adults in countries 
with low and intermediate endemicity of chronic HBV infection. However, studies 
conducted in some countries e.g. Brazil (17), Taiwan (21) and Monterial (22) revealed 
that in countries where HBV infection is highly endemic, sexual transmission 
generally does not account for a high percentage of new cases because most 
persons are already infected during childhood.  
Percutaneous exposures (e. g. unsafe injections):  
Therapeutic injections are a major source of transmission of HBV and other 
blood borne pathogens in many developing countries, where up to 50% of 
injections are administered with needles and syringes that are reused without 
sterilization, study of unsafe injections and the transmission of hepatitis B and C in 
Pakistan1995 (23). Other sources of percutaneous HBV transmission in medical 
care settings include the reuse of contaminated medical or dental equipment, 
improper use of multi–dose medication vials, and sharps injuries sustained by 
medical personnel. Blood transfusion is also a major source of HBV transmission 
in countries where the blood supply is not screened for HBsAg. In areas of high 
endemicity, the lifetime risk of HBV infection is more than 60% and most infections 
are acquired from perinatal and child–to–child transmission. When the risk of 
developing chronic infection is great in those areas, acute hepatitis B is uncommon 
because most infections in early childhood are asymptomatic. However, rates of 
chronic liver disease and liver cancer are very high (1, 3, 5, 7, 11). 
Risk Groups: 
Contacts of persons with chronic HBV infection: 
The prevalence of HBV infection among sexual and nonsexual, household 
contacts of persons with chronic HBV infection ranges from 25%–50%. The 
highest risk of infection, approximately 5% per year, is among sexual contacts. 
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Among young children living in a household with an HBsAg–positive person, as 
shown from study done in China 1992 (24) and study in Nigeria (25). Persons with 
chronic HBV infection are identified in a number of settings, including screening of 
blood donors, pregnant women, haemodialysis patients and refugees and 
immigrants, as well as through diagnostic testing of persons as part of a medical 
evaluation (5). 
Injection drug users: 
Direct parenteral exposure is the most efficient mode of HBV transmission 
in the United States. The prevalence of infection among injection drug users 
ranges from 30%–90%. Risk of infection increases with number of years of drug 
use, and >80% of injection drug users are infected after 5 years of injecting (5). 
Persons with ooccupational exposure: 
Other groups with potential occupational risk of HBV infection include public 
safety workers with high frequency exposure to blood, as shown from study done 
in Iran for Iranian oil company health workers in Teheran prior to mass vaccination 
(26). However, the prevalence of HBV infection in groups such as police officers, 
firefighters and corrections officers generally does not differ from the general 
population when adjusted for race and age. (27).  
Non–occupational risk factors: 
An increased risk of HBV infection due to occupational exposures has not 
been documented in persons infrequently exposed to blood or body fluids such as 
ward clerks, dietary workers, maintenance workers, housekeeping personnel, 
lifeguards, school teachers and persons employed in daycare. (1, 3, 11). 
Developmentally disabled persons: 
Very high rates of HBV infection were documented among residents in 
institutions for developmentally disabled before hepatitis B vaccine was used in 
these facilities. In the United States, the risk of HBV infection has declined 
substantially over the past 3 decades. However, because HBsAg–positive clients 
remain in these institutions, it should be presumed that these persons can transmit 
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HBV to other persons, especially if the disabled person behaves aggressively or 
has special medical problems (e.g. exudative dermatitis, open skin lesions) that 
increase the risk of exposure to blood or serous secretions. As shown from study 
done for a municipal house of correction in USA for hepatitis B and D (27) another 
study in Montreal 1995–96 among street youths. (22). 
Travellers to HBV–endemic regions: 
Short–term travelers to areas where HBV infection is of high or intermediate 
endemicity are generally not at risk of infection unless exposed to blood in medical, 
health care or disaster relief activities; through medical care that involves 
parenteral exposures; or through sexual or drug use activity. However, persons 
working in these areas for six months or longer have infection rates of 2%–5% per 
year (5). 
 
 
Chapter Two
 
 
 
 
 
Materials & Methods 
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Materials and Methods 
 
Study design:  
This is a descriptive cross–sectional community–based study. 
Study area: 
Khartoum State, which represents one of the 3 states in which HB vaccine 
will be introduced. The state was divided into 7 localities and these were further 
sub–divided into urban rural and camps many sectors and every sector sub divided 
into 899 villages or different haie, and camps (Khartoum State Statistical Records). 
The children <10 years of age constituted about 30%of the total population which 
is equal to 1,670,466 child (EPI Information Department, 2004). 
Study population: 
There were two study population: 
1. All children <10 years old (this age group was chosen because HB 
vaccine provides immunity for 10–15 years and this study will act as 
data base for further studies on the vaccine efficacy in preventing 
the occurrence of the disease) (1, 5, 7).  
2. Parents or any other child care taker of eligible children in the 
household.  
Inclusion criteria:  
Any child aged <10 years old, irrespective of his previous or current health 
status.  
Exclusion criteria:  
Any child aged >10 years old. 
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Sampling: 
Sample design: 
A cluster sample design was used for this study. 
Sample size: 
The sample size was calculated using the formula: n=Z2 (PQ) x 2  
   d2  
Where; 
z =  Confidence level = 1.96 corresponds to 95% in Z table  
p =  is the prevalence = 0.5 and q = (1–p) = 0.5   
d2 =  desired margin of error = 0.0039  
n =  250 x 2 (design effect) = 500 
 
Sample technique: 
A list of villages and haie in the 7 localities of Khartoum State was prepared. 
The total cumulative list of the population was done, and the cluster interval was 
calculated (the total cumulative divided by 30). First cluster was selected randomly 
according to the figure number, cluster interval added to the first cluster to identify 
the second, and this was followed until the 30 clusters completed. The sample size 
divided over 30 = number of children in each cluster (500/30=17) i.e. 17 child per 
cluster. In the field, WHO protocol of the 30 cluster sampling was followed (23). 
Distribution of clusters in Khartoum State was as shown in (Table 1) below. 
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Table (1): Name of Haie and the number of selected clusters – Khartoum State, 
2004  
 
Name of the "Haie" Selected Clusters 
Elhela eljadeda wasat 1 
Khartoum 1 & 2 2 
Eljeraf hara 1 3 
Elengaz block 1 4 
Eaid hesean block 4 east 5 
Elnaser center south elhara 9 6 
Mayo–elsalam weast part 7 
Wad emara block 2 8 
Ebad elrahman east 9 
Elmorada west 10 
Elshohada north  11 
Abusead block 9 12 
Elhara 6 hei elrawda  13 
Elhara 6 marahean  14 
Eljereaf 15 
Eluhda Elharah 9 Janoub 16 
Dar Elargham Elharah 41 17 
Haiy El kawther sq.34 18 
Elharah 16 B Elbustan 19 
Elwadi Elakhadar Shamal 20 
Haiy Elwehdaa A 21 
Elsahbeiaa Shamal 22 
Um Elguraa Wasat 23 
Elsamrab Haiy Elwefagg 24 
Eltakamoul 25 
Haiy Karkuj Shamal Janoub 26 
Elkhoujlab 27 
Um takal  28 
Eid UmDoum 29 
Eid Bilal–Elsalahabi 30 
 
Study variables: 
• Presence of HB markers. 
• Background variables: Age, gender, tribe … etc. 
• Carrier and immunity status among children. 
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• Age distribution of those infected with disease. 
• Risk factors (immigration status, history of contact with 
infection from: parents, siblings, adult resident at home, 
previous blood transfusion, blood product, contaminated 
syringe use, renal dialysis, history of jaundice, or liver cancer, 
history of illness suggesting regular use of injections, father 
and mother occupation). 
Data collection methods: 
Tools: 
1. Three to five ml of venous blood was collected from study population of 
children <10 years old. 
2. Structured interview using pre–tested and pre–coded questionnaire 
for mothers and caretakers (see annex 1, 2). 
Procedures: 
• Ethical clearance: 
The research proposal was submitted to the Research Department (FMoH) 
for the ethical clearance and to the Research Department (KSMoH), for approval 
and commitment (see annex 3). 
• Training of data collectors: 
Data collectors were selected carefully from those who have experience in 
blood collection they consisted of 6 teams composed of doctors and laboratory 
technicians. The training objective includes blood collection technique and filling 
the questionnaire. Training was for one day and the field test 2 days. 
• Field work:  
The field work took about 10 days; pre–test was done to verify the technique 
and the questionnaire. A written consent of parent of the households was taken at 
first (see annex 4, 5). All families participated in this study were enlighten in regard to 
HBV infection and the magnitude of the problem in the country. Information about 
the disease etiology, routes of transmission, prevision and the need for vaccination 
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was conveyed to them through distribution of pamphlets highlighting the 
aforementioned.  
A pretest was conducted in 4 population settings (Haie) in Khartoum State 
other than the selected clusters. The results of the pre–test were taken into 
consideration for correction and adaptation of the tools, technique and the 
questionnaire. 
Techniques: 
Blood collection: A written consent of parent or the child care taker on the 
households was taken at first, filling the questionnaire from the eligible child 
care taker was done. Then under sterilized condition using gloves, 
tourniquet and cleaning the area with sterilized swap and by 5ml syringe 
they took a 3–5 ml of venous blood into blood collection containers. The 
samples were stored in a vaccine carrier and brought to the Faculty of 
Medicine laboratory at the end of each day. At the lab, the labeled blood 
samples were prepared by extraction of the serum on daily basis and stored 
under –20oC until processed. Clinotech diagnostic EIA kits were used in 
testing the markers. Third generation Competitive EIA kits with sensitivity of 
99.8% and specificity of 99.9% were used to test the anti–HBc marker, and 
anti–HBe, sandwich EIA III generation kits with sensitivity of 99.8% and 
specificity of 100% were used for testing HBsAg, and third generation 
sandwich double Antigen EIA kits with sensitivity of 99.6% and specificity of 
99.8% were used to test anti–HBs. Internal quality control of known 
positives and negatives were used, and then ELISA reader used to read the 
results by a qualified laboratory technician under close supervision of a 
virologist. At first, all the samples were tested for the presence of anti–HBc 
than the positives were tested for HBsAg then the positives tested for 
HBeAg to detect the active liver disease and the HBsAg negatives tested for 
the presence of anti–HBs to detect the immune children, the negatives for 
HBeAg tested for the presence of Anti–HBe (29, 30).  
Questionnaire: Closed ended, pre–coded structured and pre–tested questionnaire was 
used for the household including all study variables (see annex 2). 
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Data Entry and Analysis: 
Data was entered and analyzed using SPSS. Chi–squire test, Fishers exact 
test were used. P value <0.05 was considered as significant. 
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Results 
 
General characteristics: 
 
The gender distribution of the study populaƟon  is shown  in figure (1). Out of the 
500 children below 52% were males while 48% were females.  
 
Figure (1): Distribution of Study Population by Gender – Khartoum State, 2004 
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Figure  (2)  shows  the  percentage  of  <1  year  age  group was  only  1% while  the 
majority of  the <10 years old  (81%) were  in  the age group 6–10. The percentage of 1–
5years old age group was 18%. 
 
 
Figure (2): Distribution of the Sample by Age Groups in Children <10 years Old – 
Khartoum State, 2004 
(n=500) 
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Table (2) shows that the majority (80%) of families are resident in Khartoum State 
for more than 20 years. Others vary between less than one year and 19 years.  
 
Table (2): Period of Residence Inside Khartoum State for the Families of 
Children <10 yrs – Khartoum State, 2004 
(n=500) 
Period of stay inside 
Khartoum State/year Frequency Percent 
<year 5 1.0 
1 7 1.4 
2 11 2.2 
3 12 2.4 
4 10 2.0 
5 6 1.2 
6 3 0.6 
7 6 1.2 
8 4 0.8 
9 5 1.0 
10 5 1.0 
11 1 0.2 
12 6 1.2 
13 3 0.6 
14 1 0.2 
15 7 1.4 
16 1 0.2 
17 2 0.4 
18 1 0.2 
19 1 0.2 
>20 403 80.6 
Total 500 100 
 
 
 
Sero–epidemiology of Hepatitis B among 
children <10 yrs – Khartoum State, 2004 26 
The results of tested blood samples: 
The prevalence rate of previous or recent  infection (Anti–HBc marker positive)  in 
children <10 years in Khartoum State was 24.8% {95%CI, 24.84%–24.76%}. Figure (3). 
 
Figure (3): Prevalence of Anti–HBc Marker in Children <10 years Old – Khartoum 
State, 2004 
(n=500) 
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Figure (4) shows that 11.3% {95% CI, 11.21%–11.39%} out of those who were Anti–
HBc positive (124) were also HBsAg positive (chronic carrier). 
 
Figure (4): Prevalence of HBsAg Marker among those Positive for Anti–HBc in 
Children <10 years Old – Khartoum State, 2004 
(n=124) 
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None of the tested children for Anti–HBs marker (immunity) were found immuned, 
(figure 5). 
 
Figure (5): Prevalence of Anti–HBs Marker among those Negative for HBsAg in 
Children <10 years Old – Khartoum State, 2004 
(n=110) 
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Figure  (6) shows  that 78.6%  {95% CI, 78.35%–78.86%} of  those who were HBsAg 
positive were also positive for HBeAg marker (rate of  infectivity among carrier). The rest 
21.4% were HBeAg negative.  
 
Figure (6): Prevalence of HBeAg Marker among those Positive for HBsAg in 
Children <10 years – Khartoum State, 2004 
(n=14) 
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Figure  (7)  shows  that 33.3%  {95% CI, 32.74% – 33.86%} of HBeAg negative were 
positive for anti–HBe.  
 
Figure (7): Prevalence of Anti–HBe Marker Among those Negative for HBeAg in 
Children <10 years Old – Khartoum State, 2004 
(n=3) 
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(A) Summary result for the investigated blood samples 
 
As shown from the figures above that from the 500 sample tested for the presence 
of HBV marker the prevalence rate was as follow: 
? The prevalence of recent or past HBV infection (anti–HBc positives) was found 
to be 24.8% {95% CI, 24.76% – 24.84%}. 
? The prevalence of carrier rate (HBsAg positive) was 11.3% {95% CI, 11.21% – 
11.39%}.  
? None of those children who were HBsAg negative was found to be immuned 
(anti–HBs positive). 
? The prevalence of high infectivity among carriers (HBeAg positive) was 78.6% 
{95% CI, 78.35% – 78.86%}. 
? The rate of HBeAg sero–coversion was found to be 33% {95% CI, 32.74% – 
33.86%}.  
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The relation between HBV markers and General risk factors: 
The anti–HBc positive was equally distributed among males and females. There is 
no statistically significant difference concerning the prevalence of infection (Anti–HBc +ve 
marker) and gender, (figure 8). 
 
Figure (8): Distribution of Anti–HBc Marker by Gender among Children <10 
years Old – Khartoum State, 2004 
(n=500) 
 
50%
50%
53%
47%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pe
rc
et
an
ge
+ve -ve
Male Female
 
P=0.679 
 
 
Sero–epidemiology of Hepatitis B among 
children <10 yrs – Khartoum State, 2004 33 
Figure (9) shows that the carrier rate was higher among females (57%) than males 
(43%)  in  children <10  years  in Khartoum  State, 2004. However  there was no  statistical 
significant difference between males and females concerning HB carrier rate (HBsAg +ve). 
 
Figure (9): Distribution of HBsAg Marker by Gender Among those Positive for Anti–HBc 
in Children <10 years Old in – Khartoum State, 2004 
(n=124) 
 
 
P=0.778 
 
43%
57%
51%
49%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pe
rc
et
an
ge
+ve -ve
Male Female
Sero–epidemiology of Hepatitis B among 
children <10 yrs – Khartoum State, 2004 34 
The distribution of positive HBeAg marker was more prevalent among males (55%) 
compared to females (45%) in children <10 years in Khartoum State, 2004. There was no 
statistical  significant  difference  between  both  gender  concerning  HB  infective  carrier 
(HBeAg +ve), (figure 10). 
 
Figure (10): Distribution of HBeAg Marker by Gender among those HBsAg 
Positive in Children <10 years Old in – Khartoum State, 2004 
(n=14) 
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Figure (11) shows that 26% of children aged 6–10years, and 20% of children aged 
1–5years  were  positive  for  anti–HBc  marker.  No  positive  child  was  detected  among 
children <1 year. However results are not statistically significant.  
Figure (11): Distribution of Anti–HBc Marker by Age Group among 
Children <10 years Old in – Khartoum State, 2004 
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Figure  (12)  shows  that 11.3% of children aged 6–10years, and 11.1% of children 
aged 1–5years were found positive for HBsAg. No HBsAg was detected among children <1 
year. However,  there was  no  statistical  significant  difference  between  presence HBsAg 
and age group studied.  
 
Figure (12): Distribution of HBsAg Marker by Age Group among those Positive 
for Anti–HBc in Children <10 years Old in – Khartoum State, 2004 
(n=124) 
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Figure  (13)  shows  that  9  children  (75%)  aged  6–10years,  and  2  children  (100%) 
were  infectious carriers  (HBeAg +ve marker), no positive HBeAg marker among <1 year 
children. However, there was no statistical significant difference between infective carrier 
and age group studied.  
 
Figure (13): Distribution of HBeAg Marker by Age Group Among those Positive 
for HBsAg in Children <10 years Old in Khartoum State, 2004. 
(n=14) 
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Table  (3)  shows  that  the  infection was more prominent among Manasser  (75%), 
Rubatab (66%), and the refugees (60%). The prevalence of anƟ–HBc among other tribes in 
the  study  populaƟon  was  ranging  between  0%  among  Fong  tribe  and  40%  among 
Hassaneia. There was a statistical significant relation (p <0.05 at CI 95%) between hepatitis 
B infection (Anti–HBc +ve) and children's family tribe. 
 
Table (3): Distribution of Anti–HBc Marker by Tribe in Children <10 yrs – 
Khartoum State, 2004 
(n=500) 
 
Anti–HBc test 
Tribe 
+ve –ve 
Total 
Gaalien  21 (21.6%) 76 (78.4%) 97 (100%) 
Bataheen 2 (25%) 6 (75%) 8 (100%) 
Gumooia 5 (29.4%) 12 (70.6%) 17 (100%) 
Danagla  3 (11.5%) 23 (88.5%) 26 (100%) 
Hassaneeya  6 (40%) 9 (60%) 15 (100%) 
Shawaiga  4 (20%) 16 (80%) 20 (100%) 
Musalammiya  1 (25%) 3 (75%) 4 (100%) 
Mahas & Halfawiyeen 10 (38.5%) 16 (61.5%) 26 (100%) 
Mawaleed 3 (10%) 27 (90%) 30 (100%) 
Fallatta  5 (23.8%) 16 (76.2%) 21 (100%) 
Bega  5 (25%) 15 (75%) 20 (100%) 
Denka&Sholok 8 (29.6%) 19 (70.4%) 27 (100%) 
Rufa'ieen  1 (8.3%) 11 (91.7%) 12 (100%) 
Noba & Brgo 29 (23.0%) 97 (76.0%) 126 (100%) 
Elfong 0 3 (100%) 3 (100%) 
Fore  13 (36.1%) 23 (63.9%) 36 (100%) 
Rubatab 2 (66.7%) 1 (33.3%) 3 (100%) 
Foreigners (refugees) 3 (60%) 2 (40%) 5 (100%) 
Manaseer  3 (75%) 1 (25%) 4 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
P=0.047 
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There was  no  statistical  significant  relation  between  hepatitis  B  carriers  (HBsAg 
+ve) and children's family tribe (p> 0.05 at CI 95%) as shown  in Table (4) below and the 
infection was restricted to just 6 tribe 57% of them among Kordufan tribe, 14% Darfur and 
7% in Bataheen, Mahas, east and Manaseer tribe,  
 
Table (4): Distribution of HBsAg Marker among those Positive for Anti–HBc by 
Tribe – Khartoum State, 2004 
(n=124) 
HBsAg test 
Tribe 
+ve –ve 
Total 
Gaalien  0 21 (100%) 21 (100%) 
Bataheen 1 (50%) 1 (50%) 2 (100%) 
Gumooia 0 5 (100%) 5 (100%) 
Danagla  0 3 (100%) 3 (100%) 
Hassaneeya  0 6 (100%) 6 (100%) 
Shawaiga  0 4 (100%) 4 (100%) 
Musalammiya  0 1 (100%) 1 (100%) 
Mahas & Halfawiyeen 1 (10%) 9 (90%) 10 (100%) 
Mawaleed 0 3 (100%) 3 (100%) 
Fallatta  1 (20%) 4 (80%) 3 (100%) 
Bega  0 5 (100%) 5 (100%) 
Denka  0 8 (100%) 8 (100%) 
Rufa'ieen  0 1 (100%) 1 (100%) 
Noba&Brgo 8 (27.6%) 21 (72.4%) 29 (100%) 
Elfong 2 (15.4%) 11 (84.6%) 13 (100%) 
Fore  0 2 (100%) 2 (100%) 
Rubatab 0 3 (100%) 3 (100%) 
Foreigners (refugees) 1 (33.3%) 2 (66.7%) 3 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.243 
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As shown in table (5), there was no statistical significant relation between hepatitis 
B  infective  carriers  (HBeAg +ve) and  children's  family  tribe  (p> 0.05 at CI 95%) and  the 
infecƟon was restricted to just 4 tribe 64% of them among Kordufan tribe, 18% Darfur and 
9% in Manseer and Fallatta tribe,  
 
Table (5): Distribution of HBeAg Marker Among those Positive for HBsAg by 
Tribe in Children <10 yrs – Khartoum State, 2004 
(n=14) 
 
 
HBeAg test 
Tribe 
+ve –ve 
Total 
Bataheen  0 1 (100%) 1 (100%) 
Mahas & Halfawiyeen 0 1 (100%) 1 (100%) 
Fallatta  1 (100%) 0 1 (100%) 
Noba & Brgo  7 (87.5%) 1 (12.5%) 8 (100%) 
Fore  2 (100%) 0 2 (100%) 
Manaseer 1 (100%) 0 1 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
 
P=0.117 
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In  table  (6),  there  was  no  statistical  significant  relation  between  hepatitis  B 
immune  carriers  (HBeAb  +ve)  and  children's  family  tribe  (p>  0.05  at  CI  95%)  and  the 
immunity was restricted to just 1 tribe which is Kordufan tribe,  
  
 
Table (6): Distribution of Anti–HBe Marker among those Negative for HBeAg by 
Tribe in Children <10 yrs – Khartoum State, 2004 
(n=3) 
 
 
Anti–HBe test 
Tribe 
+ve –ve 
Total 
Bataheen  0 1 (100%) 1 (100%) 
Mahas & Halfawiyeen 0 1 (100%) 1 (100%) 
Noba & Bargo  1 (100%) 0 1 (100%) 
Total 1 (33.3%) 2 (66.7%) 3 (100%) 
 
P=0.223 
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In  table  (7),  there  was  no  statistical  significant  relation  between  hepatitis  B 
infection  (HBcAb +ve) and  children's  family  residence  inside Sudan  (p> 0.05 at CI 95%), 
79% of posiƟve were  resident  inside Khartoum  and  the others distributed between 10 
different  states  (Gezira, North Kordufan, Northern, River Nile, West Darfur  (3%),  South 
Darfur, Kassala, Unity and Bahr Elgabal (1%).  
  
Table (7): Relation Between Anti–HBc Marker and Residence of the Child's 
Family inside Sudan – Khartoum State, 2004 
(n=500) 
Anti–HBc test Residence inside 
Sudan +ve –ve 
Total 
Khartoum 98 (25.1%) 292 (74.9%) 390 (100%) 
Gezira 4 (33.3%) 8 (66.7%) 12 (100%) 
North Kordufan 4 (15.4%) 22 (84.6%) 26 (100%) 
Northern 4 (23.5%) 13 (76.5%) 17 (100%)  
River Nile 4 (40%) 6 (60%) 10 (100%)  
Outside Sudan 2 (33.3%) 4 (66.7%) 6 (100%) 
S. Darfur 1 (11.1%) 8 (88.9%) 9 (100%) 
Kassala 1 (50%) 1 (50%) 2 (100%)  
Unity 1 (50%) 1 (50%) 2 (100%) 
West Kordufan 0 7 (100%) 7 (100%)  
W. Darfur 4 (44.4%) 5 (55.6%) 9 (100%) 
Baher elgabal 1 (50%) 1 (50%) 2 (100%) 
Blue Nile 0 3 (100%) 3 (100%) 
Sinnar 0 2 (100%) 2 (100%) 
White Nile 0 2 (100%) 2 (100%)  
Jongoly 0 1 (100%) 1 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
P=0.605 
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There was no statistical significant  relation between hepatitis B  infection  (HBsAg 
+ve) and children's family residence inside Sudan (p> 0.05 at CI 95%), as shown in table (8) 
and the posiƟves were restricted to 4 states 79% of them resident inside Khartoum State 
and 7% from North Kordufan, Northern and West Darfur.  
 
Table (8): Relation between HBsAg Marker and Residence of the Child's Family 
inside Sudan – Khartoum State, 2004 
(n=124) 
 
HBsAg test 
Residence inside Sudan 
+ve –ve 
Total 
Khartoum 11 (11.2%) 87 (88.8%) 98 (100%) 
Gezira 0 4 (100%) 4 (100%) 
North Kordufan 1 (25%) 3 (75%) 4 (100%) 
Northern 1 (25%) 3 (75%) 4 (100%) 
River Nile 0 4 (100%) 4 (100%) 
Outside Sudan 0 2 (100%) 2 (100%) 
South Darfur 0 1 (100%) 1 (100%) 
Kassala 0 1 (100%) 1 (100%) 
Bantiu 0 1 (100%) 1 (100%) 
West Darfur 1 (25%) 3 (75%) 4 (100%) 
Baher elgabal 0 1 (100%) 1 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
P=0.946 
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In  table  (9),  there  was  no  statistical  significant  relation  between  hepatitis  B 
infective carriers (HBeAg +ve) and children's family residence  inside Sudan (p> 0.05 at CI 
95%), and the posiƟves were restricted to 3 states 82% of them resident inside Khartoum 
State and 9% from North Kordufan and West Darfur.  
 
 
Table (9): Relation Between HBeAg Marker and Residence of the Child's Family 
Inside Sudan – Khartoum State, 2004 
(n=14) 
 
 
HBeAg test Residence inside 
Sudan +ve –ve 
Total 
Khartoum 9 (81.8%) 2 (18.2%) 11 (100%) 
North Kordufan 1 (100%) 0 1 (100%) 
Northern 0 1 (100%) 1 (100%) 
West Darfur 1 (100%) 0 1 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P=0.233 
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There was no statistical significant relation between hepatitis B  infective carriers 
(HBeAb +ve) and children's family residence inside Sudan (p> 0.05 at CI 95%), as shown in 
table (10) and the posiƟves were 100% resident inside Khartoum State which is one case.  
  
 
Table (10): Relation Between Anti–HBe Marker and Residence of the Child's 
Family Inside Sudan – Khartoum State, 2004 
(n=3) 
 
 
Anti–HBe test Residence inside 
Sudan +ve –ve 
Total 
Khartoum 1 (50%) 1 (50%) 2 (100%) 
Northern 0 1 (100%) 1 (100%) 
Total 1 (33.3%) 2 (66.7%) 3 (100%) 
 
P=1.000 
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In table (11), only 4 posiƟve cases were from outside Sudan 3 of them from Eritrea 
(75%) and one from central Africa (25%), there was statistical significant relation between 
hepaƟƟs B infecƟon (HBcAb +ve) and children's family residence outside Sudan (p< 0.05 at 
CI 95%). The other positive marker has no history of residence outside Sudan. 
 
 
 
Table (11): Relation Between Anti–HBc Marker and Child's Family Migrated 
from Outside Sudan – Khartoum State, 2004 
(n=8) 
 
 
Anti–HBc test 
Country migration  
+ve –ve 
Total 
Saudi Arabia 0 1 (100%) 1 (100%) 
Emirates 0 1 (100%) 1 (100%) 
 Central Africa 1 (100%) 0 1 (100%) 
Czechoslovakia 0 1 (100%) 1 (100%) 
Eritrea 3 (100%) 0 3 
Chad  0 1 (100%) 1 (100%) 
Total 4 (50%) 4 (50%) 8 (100%) 
 
P=0.036 
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(B) Summary for the relation with the general risk factors 
 
 
• Figures 8 – 10 show that HBV marker i.e. anti–HBc, HBsAg, and HBeAg 
were statistically insignificant with gender. 
• Anti–HBs was not detected in those negative for HBsAg. 
• Age group distribution was statistically insignificant with all HBV markers, 
(figures 11 – 13). 
• Table (3) shows a statistical significant relation between family tribe and 
anti–HBc. This marker was more prominent among Manaseer (75%), 
Rubatab (66%) and Refugees (60%). P= 0.047. 
• Family tribe was statistically insignificant with all other HBV markers 
investigated (tables 4 – 6).  
• Tables (7 – 10) show residence in Khartoum State was statistically 
insignificant with all HBV markers.  
• A statistical significant relation was detected between refugees and anti–
HBc, p= 0.036 (table 11). 
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Risk factors related to child: 
 
 
 
The  first  risk  factor  related  to  the  positive  child  for  HBcAb  marker  was  the 
presence of a history of previous blood or blood products  transfusion and as  shown  in 
table  (12)  below  there was  statistical  significant  relation between HB  infection  (HBcAb 
+ve)  and  history  of  previous  blood  or  blood  products  transfusion  (p<0.05  at  CI  95%) 
although  just 3%  (4/124) of posiƟves had a history of previous blood or blood products 
transfusion. 
 
Table (12): Relation between Anti–HBc Marker and Child History of Previous 
Blood or blood products Transfusion in Children <10 yrs – Khartoum State, 2004 
(n=500) 
 
 
Anti–HBc test History of blood 
transfusion +ve –ve 
Total 
Yes 4 (66.7%) 2 (33.3%) 6 (100%) 
No 120 (24.3%) 374 (75.7%) 494 (100%) 
Total 124 (24.8%) 376 (75.2%) 55 (100%) 
 
P=0.017 
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When the presence of the history of previous blood or blood products transfusion 
was  tested  against  the  positives  for  HBsAg  marker  it  shows  no  statistical  significant 
relation  (p>0.05 at CI 95%) as shown  in table  (13), 0%  (0/14) carriers  (HBsAg +ve) had a 
history of previous blood or blood products transfusion.  
 
 
Table (13): Relation between HBsAg Marker and Child History of Previous Blood 
or blood products Transfusion – Khartoum State, 2004 
(n=124) 
 
HBsAg test History of blood 
transfusion +ve –ve 
Total 
Yes 0 4 (100%) 4 (100%) 
No 14 (11.7%) 106 (88.3%) 120 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.468 
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Table  (14)  shows  that 35%  (44/124) of positive  for HBcAb marker had history of 
unsafe  injecƟon while  9%  (11/124)  don’t  know  or  don't  remember,  and  there was  no 
statistical significant relation concerning hepatitis B  infection (HBcAb +ve) and history of 
unsafe injection (p>0.05 at CI 95%).  
 
 
 
Table (14): Relation between Anti–HBc marker and the history of unsafe 
injection in children <10 yrs – Khartoum State, 2004 
(n=500) 
 
 
Anti–HBc test History of unsafe 
injection +ve –ve 
Total 
Yes 44 (23.7%) 142 (76.3%) 186 (100%) 
No 69 (24%) 219 (76%) 288 (100%) 
I don't know 11 (42.3%) 15 (57.7%) 26 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
 
P=0.105 
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In  table  (15)  36%  (5/14)  of  posiƟve  for  HBsAg  marker  had  history  of  unsafe 
injecƟon while 14%  (2/14) don’t know or don't  remember, and  there was no  statistical 
significant  relation  concerning  hepatitis  B  carriers  (HBsAg  +ve)  and  history  of  unsafe 
injecƟon (p>0.05 at CI 95%). 
 
 
 
Table (15): Relation between HBsAg Marker and History of Unsafe Injection – 
Khartoum State, 2004 
(n=124) 
 
HBsAg test History of unsafe 
injection +ve –ve 
Total 
Yes 5 (11.4%) 39 (88.6%) 44 (100%) 
No 7 (10.1%) 62 (89.9%) 69 (100%) 
I don't know 2 (18.2%) 9 (81.8%) 11 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.736 
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27% (3/11) of posiƟve for HBeAg marker had history of unsafe injecƟon while 18% 
(2/11)  don’t  know  or  don't  remember,  and  there was  no  statistical  significant  relation 
concerning  hepatitis  B  infective  carriers  (HBeAg  +ve)  and  history  of  unsafe  injection 
p>0.05 at CI 95%) as was shown in table (16). 
 
Table (16): Relation between HBeAg Marker and History of Unsafe Injection – 
Khartoum State, 2004 
(n=14) 
 
HBeAg test History of unsafe 
injection +ve –ve 
Total 
Yes 3 (60%) 2 (40%) 5 (100%) 
No 6 (85.7%) 1 (14.3%) 7 (100%) 
I don't know 2 (100%) 0 2 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P=0.410 
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In table  (17), 100% of posiƟve  for HBeAb marker had history of unsafe  injection, 
and there was no statistical significant relation between HBeAb +ve marker and history of 
unsafe injecƟon p>0.05 at CI 95%. 
 
 
Table (17): Relation between Anti–HBe Marker and History of Unsafe Injection 
– Khartoum State, 2004. 
(n=3) 
 
Anti–HBe test History of unsafe 
injection +ve –ve 
Total 
Yes 1 (50%) 1 (50%) 2 (100%) 
No 0 1 (100%) 1 (100%) 
I don't know 0 0 0 
Total 1 (33.3%) 2 (66.7%) 3 (100%) 
 
P=0.386 
 
 
Chapter Three
 
 
 
 
 
Results 
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9% (11/124) of posiƟve for HBcAb marker had history of Jaundice, and there was 
no statistical significant relation concerning hepatitis B  infection  (HBcAb+ve) and history 
of Jaundice (p>0.05 at CI 95%) as shown in table (18). 
 
 
 
Table (18): Relation between Anti–HBc Marker and Child History of Jaundice in 
children <10 yrs – Khartoum State, 2004 
(n=500) 
 
 
Anti–HBc test History of 
Jaundice +ve –ve 
Total 
Yes 11 (23.4%) 36 (76.6%) 47 (100%) 
No 113 (25.1%) 338 (74.9%) 451 (100%) 
I don't know 0 2 (100%) 2 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
 
P=0.696 
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No  statistical  significant  relation  concerning  hepatitis  B  carriers  (HBsAg+ve)  and 
history of  Jaundice  (p>0.05 at CI 95%) and 21%  (3/14) of positive  for HBsAg marker had 
history of Jaundice, as shown in table (19).  
 
 
Table (19): Relation between HBsAg Marker and Child History of Jaundice – 
Khartoum State, 2004 
(n=124) 
 
HBsAg test History of 
Jaundice +ve –ve 
Total 
Yes 3 (27.3%) 8 (72.7%) 11 (100%) 
No 11 (9.7%) 102 (90.3%) 113 (100%) 
I don't know 0 0 0 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.079 
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In  table  (20),  27%  (3/11)  of  posiƟve  for HBeAg marker  had  history  of  Jaundice, 
while  73%  no  history  of  Jaundice  and  there  was  no  statistical  significant  relation 
concerning infective carriers (HBeAg+ve) and history of Jaundice (p>0.05 at CI 95%). 
 
 
Table (20): Relation between HBeAg Marker and Child History of Jaundice – 
Khartoum State, 2004. 
 (n=14) 
 
HBeAg test History of 
Jaundice +ve –ve 
Total 
Yes 3 (100%) 0 3 (100%) 
No 8 (72.7%) 3 (27.3%) 11 (100%) 
I don't know 0 0 0 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P=0.308 
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Table (21) shows that from Jaundice 18% (2/11) acquired it at age <1 year and 36% 
(4/11) acquired it at 1–5years and 45% (5/11) acquired it at older age 6–10years, though 
no  statistical  significant  relation  between  rate  of  infection  (HBcAb  +ve)  and  age  of 
acquiring Jaundice (p >0.05 at CI 95%). 
 
 
Table (21): Relation between Anti–HBc Marker and Age at which child Acquired 
Jaundice – Khartoum State, 2004. 
(n=47) 
 
 
Anti–HBc test The age at which child 
acquired Jaundice +ve –ve 
Total 
<1 year 2 (66.7%) 1 (33.3%) 3 (100%) 
1–5 years 4 (16.7%) 20 (83.3%) 24 (100%) 
6–10years 5 (25%) 15 (75%) 20 (100%) 
Total 11 (23.4%) 36 (76.6%) 47 (100%) 
 
P=0.152 
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Although no  statistical  significant  relation between  carrier  rate  (HBsAg +ve) and 
age of acquiring  Jaundice  (p>0.05 at CI 95%)  though as  shown  in  table  (22)  from  those 
positive for HBsAg marker 33% (1/3) had Jaundice at age <1 year and 33% (1/3) acquired it 
at 1–5years and 33% (1/3) acquired it at older age 6–10years. 
 
 
 
 
Table (22): Relation between HBsAg Marker and Age at Which Child Acquired 
Jaundice – Khartoum State, 2004 
(n=11) 
 
 
HBsAg test The age at which child 
acquired Jaundice +ve –ve 
Total 
<1 year 1 (50%) 1 (50%) 2 (100%) 
1–5years 1 (25%) 3 (75%) 4 (100%) 
6–10years 1 (20%) 4 (80%) 5 (100%) 
Total 3 (27.3%) 8 (72.7%) 11 (100%) 
 
P=0.717 
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In  table  (23),  from  those posiƟve  for HBcAb marker 9%  (11/124) had history of 
chronic illness that required regular injections while 91% (113/124) had no history, though 
there  is  statistical  significant  relation between  infection  rate  (HBcAb+ve) and history of 
chronic illness that required regular injections (p< 0.05 at CI 95%). 
 
 
 Table (23): Relation between Anti–HBc Marker and Child History of Chronic 
Illness Required Regular Injections in Children <10 years – Khartoum State, 
2004 
(n=500) 
 
 
Anti–HBc test Child history of chronic 
illness requiring regular 
injections +ve –ve 
Total 
Yes 11 (44%) 14 (56%) 25 (100) 
No 113 (23.8%) 362 (76.2%) 475 (100) 
Total 124 (24.8%) 376 (75.2%) 500 (100) 
 
P =0.023 
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No statistical significant relation between carrier rate  (HBsAg +ve) and history of 
chronic  illness  that  required  regular  injecƟons  (p>  0.05  at  CI  95%)  though  from  those 
posiƟve for HBsAg marker 14% (2/14) had history of chronic  illness that required regular 
injecƟons while 86% (12/14) had no history. 
 
 
 
Table (24): Relation between HBsAg Marker and Child History of Chronic Illness 
Required Regular Injections – Khartoum State, 2004 
(n=124) 
 
 
HBsAg test Child history of chronic 
illness requiring regular 
injections +ve –ve 
Total 
Yes 2 (18.2%) 9 (81.8%) 11 (100%) 
No 12 (10.6%) 101 (89.4%) 113 (100%) 
Total 14 (11.3%) 110 (88.7)% 124 (100%) 
 
P =0. 449 
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In  table  (25)  from  those  posiƟve  for  HBeAg marker  18%  (2/11)  had  history  of 
chronic illness that required regular injecƟons while 82% (9/11) had no history, and there 
was no statistical significant relation between infective carriers (HBeAg +ve) and history of 
chronic illness that required regular injections (p> 0.05 at CI 95%). 
 
 
 
Table (25): Relation of HBeAg Marker and Child History of Chronic Illness 
Required Regular Injections – Khartoum State, 2004 
(n=14) 
 
HBeAg test Child history of chronic 
illness requiring regular 
injections +ve –ve 
Total 
Yes 2 (100%) 0 2 (100%) 
No 9 (75%) 3 (25%) 12 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P =1.000  
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No  statistical  significant  relation  between  HBcAb  +ve  marker  and  the  type  of 
chronic  illness that required regular  injecƟons (p>0.05 at CI 95%) and 9% (1/11) of those 
positive  for  HBcAb marker  had  history  of  chronic  blood  disease  that  required  regular 
injecƟon while 91%  (10/11) had history of  chronic  chest  infection  that  required  regular 
injection as shown in table (26).  
 
 
 
Table (26): Relation between Anti–HBc Markers and Type of Chronic Illness 
Required Regular Injections in Children <10 yrs – Khartoum State, 2004 
(n=25) 
 
 
Anti–HBc test Type of chronic illness 
required regular 
injections +ve –ve 
Total 
chronic blood disease 1 (100%) 0 1 (100%) 
Chronic chest infection  10 (24%) 14 (76%) 24 (100%) 
Total 11 (44%) 14 (56%) 25 (100%) 
 
P=0.031 
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In table (27), 100% of those posiƟve for HBsAg marker had history of chronic chest 
infection  that  required  regular  injection  and  no  statistical  significant  relation  between 
carrier  rate  (HBsAg +ve) and  the  type of  chronic  illness  that  required  regular  injections 
(p>0.05 at CI 95%). 
 
 
Table (27): Relation between HBsAg Markers and Type of Chronic Illness 
Required Regular Injections – Khartoum State, 2004 
(n=11) 
 
 
HBsAg test Type of chronic illness 
required regular 
injections +ve –ve 
Total 
Chronic blood disease 0 1 (100%) 1 (100%) 
Chronic chest infection  2 (20%) 8 (80%) 10 (100%) 
Total 2 (18.2%) 9 (81.8%) 11 (100%) 
 
P=0.626 
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(C) Summary for the relation with risk factors related to child 
 
Table (12) shows a statistical significant relation was detected between 
anti–HBc and history of blood /blood products transfusion p= 0.017. 
No statistical significant relation was detected between history of blood 
/blood products transfusion and HBsAg markers (table 13). 
Tables (14–17) show no statistical significant relation between history of 
unsafe injection and all HBV serological markers. 
 History of jaundice was statistically insignificant when tested against all 
HBV serological markers (table 18–20). 
Tables (21 and 22) show statistically insignificant relation between age at 
which the child acquired jaundice and anti–HBc and HBsAg. 
A statistical relation was detected between chronic illness requiring regular 
injections and anti–HBc P= 0.023 (table 23). 
Tables 24 and 25 show no statistical significant relation between exposure 
to regular injection and HBsAg and HBeAg. 
A statistical significant relation was detected between tribe of chronic illness 
which requires regular injections and anti–HBc p=0.031 (table 26). 
Table 27 shows no statistical significant relation between type of illness 
requiring regular injections and HBsAg.  
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Risk factors related to household contacts: 
 
In  table  (28),  9%  (9/124)  of  those  posiƟve  for  HBcAb  marker  their  fathers 
occupation  were  a  health  worker  15%  (18/124)  their  fathers  were  military  and  74% 
(92/124) were other occupations and no statistical significant relation between  infection 
rate (HBcAb +ve) and the father's occupation (p>0.05 at CI 95%). 
 
 
Table (28): Relation between Anti–HBc Markers and Children's Father 
Occupation in Children <10 yrs – Khartoum State, 2004 
(n=500) 
 
 
Anti–HBc test 
Father’s occupation 
+ve –ve 
Total 
Health worker 9 (42.9%) 12 (57.1%) 21 (100%) 
Military 18 (28.1%) 46 (71.9%) 64 (100%) 
Driver for a long time 5 (22.7%) 17 (77.3%) 22 (100%) 
Other 92 (23.4%) 301 (71.9%) 393 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
 
P=0.211 
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No statistical significant relation between carrier rate (HBsAg +ve) and the father's 
occupaƟon  (p>0.05 at CI 95%) and 21%  (3/14) of  those posiƟve  for HBsAg marker  their 
father's  occupation was  a military,  79%  (11/14)  their  fathers  are  other  occupations  as 
shown in table (29).  
 
 
 
Table (29): Relation between HBsAg Markers and Children's Father Occupation 
– Khartoum State, 2004 
(n=124) 
 
HBsAg test 
Father’s occupation 
+ve –ve 
Total 
Health worker 0 9 (100%) 9 (100%) 
Military 3 (16.7%) 15 (83.3%) 18 (100%) 
Driver for a long time 0 5 (100%) 5 (100%) 
Other 11 (12%) 81 (88%) 92 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.505 
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27%  (3/11)  of  those  posiƟve  for  HBeAg marker  their  father  occupation  was  a 
military,  73%  (8/11)  their  fathers  are  other  occupaƟons  and  no  statistical  significant 
relation between infective carriers (HBeAg +ve) and the type of father occupation (p>0.05 
at CI 95%) as shown in table (30) below. 
 
 
Table (30): Relation between HBeAg Markers and Children's Father Occupation 
– Khartoum State, 2004 
(n=14) 
 
HBeAg test 
Father’s occupation 
+ve –ve 
Total 
Health worker 0 0 0 
Military 3 (100%) 0 3 (100%) 
Driver for a long time 0 0 0 
Other 8 (72.7%) 3 (27.3%) 11 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P=1.000 
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In  table  (31),  87%  (108/124)  of  those  posiƟve  for  HBcAb marker  their mother 
occupaƟon was a housewife, and  just 3% (4/124) their mothers were health worker and 
10%  (12/124)  are  other  occupaƟons  and  no  statistical  significant  relation  between 
infection rate (HBcAb +ve) and the type of mother occupation (p>0.05 at CI 95%). 
 
 
Table (31): Relation between Anti–HBc Markers and Children's Mother 
Occupation in Children <10 yrs – Khartoum State, 2004 
(n=500) 
 
  
Anti–HBc test 
Mother’s occupation 
+ve –ve 
Total 
Housewife 108 (25.8%) 310 (74.2%) 418 (100%) 
Health worker 4 (18.2%) 18 (81.8%) 22 (100%) 
Other 12 (20%) 48 (80%) 60 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
 
P=0.473 
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93%  (13/14) of  those posiƟve  for HBsAg marker  their mother occupation was a 
housewife,  no  health worker mothers  and  7%  (1/14) were  other  occupaƟons  and  no 
statistical  significant  relation between  carrier  rate  (HBsAg +ve) and  the  type of mother 
occupation (p>0.05 at CI 95%) as shown in table (32). 
 
 
Table (32): Relation between HBsAg Markers and Children's Mother – Khartoum 
State, 2004 
(n=124) 
 
HBsAg test 
Mother’s occupation 
+ve –ve 
Total 
Housewife 13 (12%) 95 (88%) 108 (100%) 
Health worker 0 4 (100%) 4 (100%) 
Other 1 (8.3%) 11 (91.7%) 12 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.714 
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No  statistical  significant  relation between  infective  carriers  (HBeAg +ve) and  the 
type  of mother  occupaƟon  (p>0.05  at  CI  95%)  and  91%  (10/11)  of  those  posiƟve  for 
HBeAg marker their mother occupation was a housewife, no health worker mothers and 
9% (1/11) were other occupaƟons.  
 
 
Table (33): Relation between HBeAg markers and Children's Mother Occupation 
– Khartoum State, 2004 
(n=14) 
 
HBeAg test Mother 
occupation +ve –ve 
Total 
Housewife 10 (76.9%) 3 (23.1%) 13 (100%) 
Health worker 0 0 0 
Other 1 (100%) 0 1 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P=1.000 
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29% (36/124) of those posiƟve for HBcAb marker had history of unsafe injecƟon to 
resident  family member,  and  11%  (14/124)  don't  know  or  remember  if  they  had  such 
history, and no statistical significant relation between rate of  infection  (HBcAb +ve) and 
history of unsafe  injection  to  resident  family member  (p> 0.05  at CI 95%)  as  shown  in 
table (34) below.  
 
 
Table (34): Relation between Anti–HBc Markers and Family History of Unsafe 
Injection to Resident Member for Children <10 yrs – Khartoum State, 2004 
(n=500) 
 
 
Anti–HBc test Family history of 
unsafe injection +ve –ve 
Total 
Yes 36 (21.4%) 132 (78.6%) 168 (100%) 
No 7425.6%) 215 (74.4%) 289 (100%) 
I don't know 14 (32.6%) 29 (67.4%) 43 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
 
P=0.285 
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In table (35), 43% (6/14) of those posiƟve for HBsAg marker had history of unsafe 
injecƟon to resident family member, and 14% (2/14) don't know or remember if they had 
such history, and no statistical significant relation between carrier rate  (HBsAg +ve) and 
history of unsafe injection to resident family member (p> 0.05 at CI 95%).  
 
 
 
Table (35): Relation between HBsAg Markers and Family History of Unsafe 
Injection in Resident Member – Khartoum State, 2004 
(n=124) 
 
HBsAg test Family history of 
unsafe injection +ve –ve 
Total 
Yes 6 (16.7%) 30 (83.3%) 36 (100%) 
No 6 (8.1%) 68 (91.9%) 74 (100%) 
I don't know 2 (14.3%) 12 (85.7%) 14 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.384 
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No  statistical  significant  relation  between  infective  carriers  (HBeAg  +ve)  and 
history of unsafe  injecƟon  to  resident  family member  (p> 0.05  at CI 95%)  as  shown  in 
table  (36)  and  36%  (4/11)  of  those  positive  for  HBeAg marker  had  history  of  unsafe 
injecƟon to resident family member, and 18% (2/11) don't know or remember if they had 
such history.  
 
 
 
Table (36): Relation between HBeAg Markers and Family History of Unsafe 
Injection in Resident Member – Khartoum State, 2004 
(n=14) 
 
HBeAg test Family history of 
unsafe injection +ve –ve 
Total 
Yes 4 (66.7%) 2 (33.3%) 6 (100%) 
No 5 (83.3%) 1 (16.7%) 6 (100%) 
I don't know 2 (100%) 0 2 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P=0.568 
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100%  of  those  positive  for  HBeAb  marker  had  history  of  unsafe  injection  to 
resident  family member, and no statistical significant  relation between  immune carriers 
(HBeAb +ve) and history of unsafe injection to resident family member (p> 0.05 at CI 95%) 
as shown in table (37).  
 
 
 
 
 Table (37): The relation between Anti–HBe markers and family history of 
unsafe injection in resident family member for children <10 yrs – Khartoum 
State, 2004 
(n=3) 
 
 
Anti–HBe test Family history of 
unsafe injection +ve –ve 
Total 
Yes 1 (50%) 1 (50%) 2 (100%) 
No 0 1 (100%) 1 (100%) 
I don't know 0 0 0 
Total 1 (33.3%) 2 (66.7%) 3 (100%) 
 
 
P=1.000 
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Table (38) shows that 41% (51/124) of those posiƟve for HBcAb marker had history 
of  liver disease  affected  resident  family member while 59%  (73/124) had no history of 
liver disease, and no statistical significant relation between infection rate (HBcAb +ve) and 
history of liver disease affected resident family member (p> 0.05 at CI 95%).  
 
 
 
Table (38): Relation between Anti–HBc Marker and History of Any Liver Disease 
Affected Resident Member Khartoum State, 2004 
(n=500) 
 
 
Anti–HBc test History of liver 
disease affected 
resident member  +ve –ve 
Total 
Yes 51 (25%) 153 (75%) 204 (100%) 
No 73 (24.7%) 223 (75.3%) 296 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
 
P=0.931 
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In  table  (39), 29%  (4/14) of  those posiƟve  for HBsAg marker had history of  liver 
disease  affected  resident  family  member  while  71%  (10/14)  had  no  history  of  liver 
disease, and no statistical significant relation between  infection  (HBsAg +ve) and history 
of liver disease affected resident family member (p> 0.05 at CI 95%).  
 
 Table (39): Relation between HBsAg Marker and History of Any Liver Disease 
Affected Resident Member – Khartoum State, 2004. 
(n=124) 
 
HBsAg test History of liver 
disease affected 
resident member  +ve –ve 
Total 
Yes 4 (7.8%) 47 (92.2%) 51 (100%) 
No 10 (13.7%) 63 (86.3%) 73 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P=0.311 
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No  statistical  significant  relation between  infective  carrier  rate  (HBeAg +ve) and 
history  of  liver  disease  aﬀected  resident  family member  (p>  0.05  at  CI  95%)  and  18% 
(2/11) of  those posiƟve  for HBeAg marker had history of  liver disease aﬀected  resident 
family member while 82% (9/11) had no history of liver disease and this is shown in table 
(40) below.  
 
 
Table (40): Relation between HBeAg Marker and History of Any Liver Disease 
Affected Resident Member – Khartoum State, 2004 
(n=14)  
 
 
HBeAg test History of liver disease 
affected resident 
member +ve –ve 
Total 
Yes 2 (50%) 2 (50%) 4 (100%) 
No 9 (90%) 1 (10%) 10 (100%) 
Total 11 (78.6%) 3 (21.4%) 14 (100%) 
 
P=0.176 
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100%  of  those  posiƟve  for  HBeAb marker  had  history  of  liver  disease  aﬀected 
resident  family member  and  no  statistical  significant  relation  between  immune  carrier 
(HBeAb +ve) and history of  liver disease affected resident  family member  (p> 0.05 at CI 
95%) as shown in table (41). 
 
Table (41): Relation between Anti–HBe Marker and History of Any Liver Disease 
Affected Resident Member – Khartoum State, 2004 
(n=3) 
 
Anti–HBe test History of liver disease 
affected resident 
member +ve –ve 
Total 
Yes 1 (50%) 1 (50%) 2 (100%) 
No 0 1 (100%) 1 (100%) 
Total 1 (33.3%) 2 (66.7%) 3 (100%) 
 
P=1.000 
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In table (42), 2% of those posiƟve for HBcAb marker give a history of  liver cancer 
47% give history of infecƟous hepaƟƟs 2% hepaƟc fibrosis and 49% had other type of liver 
disease  that  affected  resident  family  member  and  no  statistical  significant  relation 
between  infection  rate  (HBcAb  +ve)  and  type  of  liver  disease  affected  resident  family 
member (P> 0.05 at CI 95%). 
 
 
Table (42): Relation between Anti–HBc Markers and Type of Liver Disease 
Affecting Resident Member Khartoum State, 2004. 
 (n=205) 
 
 
Anti–HBc test Type of family liver 
disease +ve –ve 
Total 
Hepatitis B  0 1 (100%) 1 (100%) 
Liver cancer 1 (20%) 4 (80%) 5 (100%) 
Infectious hepatitis 24 (20.7%) 93 (79.5%) 117 (100%) 
Hepatic fibrosis 1 (50%) 1 (50%) 2 (100%) 
Other 25 (31.3%) 55 (68.8%) 80 (100%) 
Total 51 (24.9%) 154 (75.1%) 205 (100%) 
P=0.406 
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No statistical significant relation between carrier rate (HBsAg +ve) and type of liver 
disease aﬀected resident family member (P> 0.05 at CI 95%) and 100% of those posiƟve 
for HBsAg marker give a history of infectious hepatitis as shown in table (43). 
 
 
 
Table (43): Relation between HBsAg Markers and Type of Liver Disease 
Affecting Resident Member – Khartoum State, 2004. 
(n=51) 
 
HBsAg test Type of family liver 
disease +ve –ve 
Total 
Hepatitis B  0 0 0 
Liver cancer 0 1 (100%) 1 (100%) 
Infectious hepatitis 4 (16.7%) 20 (83.3%) 24 (100%) 
Hepatic fibrosis 0 1 (100%) 1 (100%) 
other 0 25 (100%) 25 (100%) 
Total 4 (7.8%) 47 (92.2%) 51 (100%) 
 
 
P=0.181 
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In table (44), 17% (21/124) of those posiƟve for HBcAb marker had history of blood 
or blood products  transfusion  to  resident  family member while 83%  (103/124) of  them 
had no such history and no statistical relation between HB infection rate (HBcAb +ve) and 
history of blood or blood products transfusion to resident  family member  (p> 0.05 at CI 
95%). 
 
 
Table (44): Relation between Anti–HBc Markers and History of Blood or Blood 
Products Transfusion to Resident Member Khartoum State, 2004. 
(n=500) 
 
 
Anti–HBc test History of blood 
transfusion to resident 
family member +ve –ve 
Total 
Yes 21 (23.6%) 68 (76.4%) 89 (100%) 
No 103 (25.1%) 308 (74.9%) 411 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
P= 0.772 
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100% of those posiƟve  for HBsAg marker had history of blood or blood products 
transfusion  to  resident  family member while no statistical  relation between carrier  rate 
(BHsAg +ve) and history of blood or blood products transfusion to resident family member 
(p> 0.05 at CI 95%) as shown in table (45) below. 
 
 
Table (45): Relation between HBsAg Markers and History of Blood or Blood 
Products Transfusion to Resident Member Khartoum State, 2004. 
(n=124) 
 
HBsAg test History of blood 
transfusion to resident 
family member +ve –ve 
Total 
Yes 0 21 (100%) 21 (100%) 
No 14 (13.6%) 89 (86.4%) 103 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
 
P= 0.073 
 
Sero–epidemiology of Hepatitis B among 
children <10 yrs – Khartoum State, 2004 83 
In  table  (46),  just  1%  of  those  posiƟve  for HBcAb marker had  a  resident  family 
history of renal dialysis while 99% had history of renal dialysis to resident family member 
and  no  statistical  significant  relation  between  infection  rate  (HBcAb  +ve)  and  resident 
family history of renal dialysis (p> 0.05 at CI 95%). 
 
  
 
Table (46): Relation between Anti–HBc Markers and Resident Family History of 
Renal Dialysis – Khartoum State, 2004. 
(n=500) 
 
 
Anti–HBc test Resident Family 
history of renal 
dialysis +ve –ve 
Total 
Yes 1 (10%) 9 (90%) 10 (100%) 
No 123 (25.1%) 367 (74.9%) 490 (100%) 
Total 124 (24.8%) 376 (75.2%) 500 (100%) 
P=0.274 
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No  statistical  significant  relation  between  carrier  rate  (HBsAg  +ve)  and  resident 
Family history of renal dialysis (p> 0.05 at CI 95%) as shown in table (47) below and 100% 
of those positive for HBsAg marker had no resident family history of renal dialysis. 
 
Table (47): Relation between HBsAg Markers and Resident Family 
History of Renal Dialysis – Khartoum State, 2004. 
(n=124) 
 
 
 
HBsAg test Resident Family 
history of renal 
dialysis +ve –ve 
Total 
Yes 0 1 (100%) 1 (100%) 
No 14 (11.4%) 109 (88.6%) 123 (100%) 
Total 14 (11.3%) 110 (88.7%) 124 (100%) 
P=0.720 
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(D) Summary of risk factors related to house hold contacts 
 
• Tables (28 – 33) show no statistical significant relation between 
father and mother occupation and all HBV serological markers. 
• Tables (34 –37) show statistically insignificant relation between family 
history and safe injection to a resident member and all HBV 
serological makers. 
• No statistical significant relation was detected between history of liver 
disease affecting a resident family member with all HBV serological 
markers tested, (tables 38 – 41). 
•  Tables 42 and 43 show no statistical significant relation between 
type of liver disease affecting a resident family member and both 
HBsAg and anti–HBc. 
• No statistical significant relation between history of blood or blood 
products transfusion to a resident family member and HBsAg and 
anti–HBc (tables 44 and 45). 
• Tables 46 and 47 show statistically insignificant relation between 
history of renal dialysis to a resident family member and HBsAg and 
anti–HBc.  
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Discussion 
Previous studies had shown that Sudan is considered as a high endemic 
area for HBV infection8. Khartoum State is the capital state where more than 4 
million inhabitants from all over Sudan reside; more or less it represents the whole 
country with its diverse demographic features. 
In this study the distribution of the sample into males and females was 
almost equal. Infants age group (<1year) representation was very small in our 
sample. This was a limitation for this study, because there were refusals from their 
parents to take blood sample. This could be attributed to the culture of Sudanese 
families and the care given to this age group, and the difficulty of obtaining blood 
sample from them as perceived by their mothers and caretakers. Lack of 
awareness in regard to HBV infection and its route of transmission might be one of 
the reasons behind this refusal. In addition there may be no motivation for those 
families to engage their babies to blood withdrawal technique without perceived 
risk. Therefore, the results for this cohort age group will not be generalized to the 
whole population.  
This study showed that the prevalence of HBV infection (anti–HBc +ve) was 
24.8% among children under 10 years old. This result reflects the magnitude of the 
problem in Khartoum State and it may raise a concern in regard to the vertical 
transmission of the virus. The obtained prevalence rate is similar to the reported 
finding from many studies done in children at the same age before HB vaccine 
being introduced in 1993 in Taiwan (31). However, the result was less than a study 
conducted in Taiwan 1999 15 years after mass vaccination campaign (21). Among 
those infected the carrier rate (HBsAg) was11.3%, which is in accordance with the 
results obtained from studies conducted in Taiwan in 1993 (31) and in Turkey in 
1999 (16). However the carrier rate was higher than that found in Taiwan in 1999 
before vaccine introduction (31), and lower than that found in a study in China (24). 
HBV infection is now almost completely preventable by immunization in 
populations in which the infection is highly endemic. Routine childhood 
immunization has led to dramatic decreases in the prevalence of chronic infection 
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as well as decline in childhood mortality from hepatocellular carcinoma in many 
countries of hyper endemicity like Sudan. Still there is a certain number neither of 
children that had no serological evidence of immunity among them (anti–HBs) 
neither self–built immunity, nor by vaccination. This can be explained by the fact 
that the vaccine was not yet introduced into the routine immunization program in 
the country as no child gave history of previous vaccination or they may be in the 
convalescent period were both HBsAg and the anti–HBs are at very low 
concentration. The findings of this study differ from all studies done before vaccine 
introduction that were at least a small percentage of sero–conversion exists (17, 21, 
31). In this study the rate of infectivity (HBeAg +ve) was high (79%) among those 
carriers which might indicate liver disease (5, 11). However, this will be only 
confirmed by conducting liver function tests or liver biopsy. In this stage there is 
high level of virus replication and those children may be on phase one or two of the 
chronic infection and we could not be certain whether they had acquired the 
infection perinatally or at older age. Nevertheless, the sero–conversion rate in both 
phases takes from 10 – 30 years (11) and this might explain the finding that only 
33% of them developed sero–coversion (anti–HBe).  
In most epidemiological studies, age has proved to be the most important 
determinant factor, and in many countries of the East Mediterranean Region age–
specific prevalence of infection and carrier status has not been well examined, 
which makes interpretation of the patterns of infection in these countries difficult. 
However, most of the studies in the region indicated that transmission in the region 
predominantly occurs during the early years of life, with adult transmission being 
relatively un–common, and it is known that children in hyper endemic areas got the 
infection from perinatal period (5, 11). In this study there were no statistical 
significant relations between all HB markers and age or the age at which the child 
get infected. Yet, it is marked that the distribution of age group among those 
positives for all markers was more prominent among older children (1–10 years). 
This indicates that they may get the infection at a younger age, which is strange 
finding in a hyper endemic area like Sudan or this may be just because the infant 
age group are absent and this need to be proved by other studies specific for 
infants. Also there were no statistical significant relations between all HB markers 
and Gender. The finding of this study is similar to that reported in study in Pakistan 
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(23). The distribution of all HB positives markers among females was higher than 
that among males, which is in accordance with previous studies (20, 21, 24, 31). 
The other statistically significant factor contributing to the prevalence of 
infection was the family tribes. The result of this study reviled that anti–HBc was 
more prominent among "Manaseer", "Rubatab" and Refugees as well. In regard to 
the local tribes, this can be attributed to their traditional habits in scarification and 
tattooing their checks and lips and practicing "hegama", which is part of tradition 
medicine practiced. Similar results were obtained from a study in Sudan 2002 
carried out among pregnant women (8). On the other hand, the prevalence of HBV 
infection among refugees coming from endemic countries bordering Sudan is 
expected to be high.  
The other statistical significant contributing factor found in this study was 
migration from endemic countries (refugees); most of them were coming from 
Eritrea which is a known hyper endemic area. 
The importance of determining the prevalence rate of infection and carriers 
becomes evident when determining the modes of transmission and preventive 
strategies. In developing countries there is a high risk of transmission through 
blood and blood products as shown from study in Ghana (14). The history of 
previous blood transfusion was one of the most common factors found to be 
associated with HBV infection and carrier status in the Middle East (8). According to 
the results of this study there was a statistical significant relation between 
presence of anti–HBc and child history of blood or blood products transfusion. But 
this factor had no statistical significant relation with the other positive HBV markers 
(HBsAg, HBeAg, anti–HBs, and anti–HBe). 
The last important statistically significant factor in the determination of the 
prevalence of infection rate (anti–HBc) in this study was child history of chronic 
illness that required regular injection. But this factor had no statistical significant 
relation with the other positive HBV markers (HBsAg, HBeAg, anti–HBs, and anti–
HBe). 
Other risk factors in this study was the household contacts, father and 
mother occupation, history of liver disease, blood transfusion, renal dialysis and 
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unsafe injection, were all tested in this study and was found statistically 
insignificant relation with all HB markers. 
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Conclusion: 
 
 
From this study it can be concluded that the prevalence rate of HBV 
infection among children under 10 years old in Khartoum State was very high, the 
prevalence of chronic carriers and infective carrier was also high, and the females 
were affected more than males. The infection rate and contributing risk factors 
among less than 1 year of age can not be detected properly in this study. Children 
1–10 years are at high risk of developing chronic liver disease latter in their life. 
The immunity rate for the infection was almost nil in those children, and the sero–
conversion among infective carriers was very low. 
In this study and among several risk factors studied, HBV infection was 
statically significant in relation to migration, family tribe, past history of blood/blood 
products transfusion and history of regular exposure to injections. Other risk 
factors were statically insignificant.  
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Recommendations: 
  
From this study the following recommendations were: 
1. Further detailed study is needed to determine HBV infection among infant and 
contributing risk factor. 
2. There is a grate need to introduce HB vaccine into routine immunization 
schedule in Sudan in order to protect this important age group. 
3. A study of sero–prevalence of HBV infection among pregnant women should be 
conducted to detect the perinatal transmission and hence decide on 
introduction of birth doses. 
4. Follow–up study after 5–10 years to assess the impact of introduction of the 
Hepatitis B vaccine into the routine immunization services in Sudan.  
5. Further community–based studies on the prevalence of HB among different 
Sudanese tribes and to determine the route of transmission among them.  
6. As far as the magnitude of the disease is considered, there is a felt need to 
develop a comprehensive social mobilization program to raise the awareness 
of the public in regard to HB infection in the community.  
7. To promote safe injection practices among health care providers and the public 
as well. 
8. To ensure that blood and blood products transfusion were properly screened 
for relevant HBV serological markers. 
9. To include HBV screening routinely during antenatal care sessions in all 
primary health care units.  
10. To conduct regular screening of HBV infection for refugees coming from 
endemic countries.  
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 
אאא 
אאא 
אאאאא 
אאא–אא 
ﲝ ﺓﺭﺎﻤﺘﺳﺍﺚ ﻲﺳﻭﲑﻔﻟﺍ ﺪﺒﻜﻟﺍ ﺏﺎﻬﺘﻟﺍ ﺽﺮﻣ ﺭﺎﺸﺘﻧﺍ ﺔﺒﺴﻧ )ﺏ (ﻷﺍ ﻂﺳﻭﻝﺎﻔﻃ ﻦﻣ ﻞﻗﺍ ١٠ ﺔﻳﻻﻮﺑ ﺕﺍﻮﻨﺳ 
 ،ﻡﻮﻃﺮﳋﺍ٢٠٠٥  
  
ﳉﺍﻝﻭﻷﺍ ﺀﺰ : ﻞﻔﻄﻟﺍ ﺓﺭﺎﻤﺘﺳﺍ  
 
١K אW   ?   ? 
٢K אW 
٠–١١  ? ١٢–٥٩ ? 
٥–١٠א ? 
 
 
٣K אW KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
٤K אאW 
١K אאאאW  KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
٢K אאF١Eאאא،W KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
٣K אאאW KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
 
 
٥K W 
 ?   ?   ? 
٦K אאאF،،،EW 
 ?   ?   ? 
٧K אאW 
 ?   ?   ? 
٨K אא،א 
٠–١١ ? ١٢–٥٩ ? ٥–١٠א ? 
 ? 
٩K אאא 
 ?   ?   ? 
 
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١٠K אאא 
 ?  אאא? 
  ?    ? 
،FWE KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
 ? 
 
ﱐﺎﺜﻟﺍ ﺀﺰﳉﺍ :ﲔﻄﻟﺎﺨﳌﺍ ﺓﺭﺎﻤﺘﺳﺍ:  
١K אW 
  ?   ? 
   ? 
،FWE KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
٢K אW 
  ? אא ? 
،FWE KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
 
٣K אאאאאF،،EW 
 ?   ?   
٤K אאאא 
 ?   ?   
٥K א،א 
 אאאFE  ?  א ? 
א   ?  א ? 
،FWE KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
   ? 
٦K אאאW 
 ?   ?   ? 
٧K אאאG 
 ?   ?   
،FWE KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK 
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Part I: Child questions: 
 
1. Sex:  Male  ? Female  ? 
2. Age 
0–11 months ? 12–59 months ? 
5–10 yrs  ? 
3. Tribe:  ………………………. 
4. Place of origin: 
4.1 If inside Sudan which state? ………………….. 
4.2 If outside Sudan, which country?……………… 
4.3 If your answer (4.1.) specify the residence inside Khartoum State 
…………………………………… 
5. Has your child received blood transfusion or any blood products before?  
Yes ?  No  ? 
6. Has your child been exposed to any kind of unsterile injections before? 
Yes ?  No  ? 
7. Was your child infected with Jaundice before? 
Yes ?  No  ? 
8. If answer for the previous question was yes how old was the child? 
10–11month ? 1–5 yr  ? 
5–10 year  ? Not applicable ? 
 
9. Was the child suffering form any chronic disease requiring regular injection? 
Yes ?  No  ? 
10. If the answer for question (9) is yes, specify which chronic disease?  
Renal failure ? Chronic hematological diseases ? 
Diabetes  ? TB    ? 
Other, specify: ………………………  
NA   ? 
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Part II: Close contacts Questionnaire: 
1. Occupation of the father: 
Health worker  ?  Military personal ? 
Heavy truck driver ? 
2. Occupation of the mother 
Housewife  ?  Health worker  ? 
3. Was any of the family member who are residing at home with the child exposed to any 
kind of unsterile injection before? 
Yes ?  No  ? 
4. Is there any resident family member affected with any liver disease?  
Yes ?  No  ? 
5. If previous answer is yes, specify which disease? 
Jaundice ? Liver cancer ? Liver cirrhosis ? 
Others, specify: …………………   NA  ? 
6. Has any member of the family received blood or blood products before?  
Yes  ?  No  ? 
7. Did any residing family member under go renal dialysis before? 
Yes ?  No  ? 
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Hepatitis B prevalence among <10 year old children in Khartoum State, 2004 
 
 
 
Introduction: 
 Hepatitis B is serious viral disease that affect the Liver, all age groups are susceptible, and 
the most vulnerable group are the under one children because 25–90% of them don’t show signs 
and they became carriers. Symptoms appear after the age of 20 years. Hepatitis B can prevented 
through vaccinating the under one children. 
Route of transmission of the disease: 
• From infected mother to her born baby during delivery. 
• Through the blood and blood products transfusion. 
• From an infected child to a healthy one. 
• Through sexual contact. 
 Signs of the diseases: 
• Can present as carrier state without symptoms and signs. 
• Or Jaundice, abdominal pain, Liver enlargement, fever, loss of appetite, nausea and 
vomiting. 
 Complications: 
• 30% of carriers die due to liver carcinoma or liver cirrhosis in the elderly. 
• Studies showed that incidence rate among adult in Sudan is 4–30%, but prevalence among 
children is un known, and this study is the first of its kind to determine the magnitude of the 
infection among children before the introduction of the Hepatitis B vaccine in the 
Immunization programme. We hope that you cooperate with us by your agreement to take 
a blood sample (5CC) from your child for testing against the infection which will help us in 
the prevention of the disease and the protection of Sudan children. 
 
 
 
 
 
I, the guardian of the child …………………………. Consent for the participation of my child in 
this study after reading and understanding the objectives above and agree that (5CC) of venous 
blood can drown from him, and that the researcher is free of any responsibility towards my 
child or to inform us about the result. 
 
NB:  There will pamphlets distributed for advices and education. 
 
 
 
Name:   ……………………………………………..  
 
Signature:  ……………………………………………..   Date:  /  / 2004  
 
  
 
Informed consent
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